Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 1, 2011, Pages 133-135

  Treon, Steven P ^a   Hanzis, Christina ^a   Tripsas, Christina ^a   Ioakimidis, Leukothea ^a   Patterson, Christopher J ^a   Manning, Robert J ^a   Sheehy, Patricia ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BENDAMUSTINE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN M; NUCLEOSIDE DERIVATIVE; OFATUMUMAB; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANTICOAGULANT THERAPY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEMATOCRIT; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOGLOBULIN BLOOD LEVEL; LARGE CELL LYMPHOMA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; PLASMAPHERESIS; PROGRESSION FREE SURVIVAL; RELAPSE; SUPERFICIAL THROMBOPHLEBITIS; THROMBOPHLEBITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; WALDENSTROEM MACROGLOBULINEMIA;

EID: 79953681626     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2011.n.030     Document Type: Conference Paper

References (14)

1. Leoni LM, Bailey B, Reifert J, et al. Bendamustine displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14:309-17. (Pubitemid 351378007)
2. Cheson BD, Rummel MJ. Bendamustine: Rebirth of an old drug. J Clin Oncol 2009; 27:1492-501.
3. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008; 26:204-10.
4. Kahl B, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 2010; 116:106-14.
5. Rummel MJ, Al-Batran SE, Kim S-Z, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade Non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:3383-9.
6. Robinson KS, Williams ME, van der Jagt RH et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:4473-9.
7. Rummel MJ, von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the firstline treatment of pati ents with follicular, indolent and mantle cell lymphomas: Results of a randomized phase III study of the Study Group Indolent Lymphomas (StiL).Blood 2008; 112: (abstract 2596).
8. Rummel MJ, von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with Waldenstrom's macroglobulinemia-First interim results of a randomized phase III study of the Studygroup Indolent Lymphomas (StiL).Proceedings of the 5th International Workshop on Waldenstrom's macroglobulinemia, Stockholm, Sweden 2008; Abstract 139.
9. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma 2006; 6:380-3.
10. Treon SP, Branagan AR, Ioakimidis L, et al. Long term outcomes to fludarabine and rituximab in Waldenstrom's macroglobulinemia. Blood 2009; 113:3673-8.
11. Treon SP. How I treat Waldenstrom's macroglobulinemia. Blood 2009; 114:2375-85.
12. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2009; 27:120-6.
13. Rummel MJ, Tenzer A, Niederle N, et al. No elevated rates of treatment-related myelodysplastic syndromes and second solid tumors following therapy with bendamustine compared with other anti-lymphoma regimens for low-grade non-Hodgkin's lymphoma. Blood 2010; 116: (abstract 3090).
14. Schmidt-Hieber M, Busse A, Reufi B, et al. Bendamustine, but not fludarabine, exhibits low stem cell toxicity in vitro. J Cancer Res Clin Oncol 2009; 135:227-34.